Published in N Engl J Med on September 16, 2010
Ig PRx in AECOPD: Pilot Study | NCT02690038
Dyspnea in COPD: Relationship With Exacerbations Frequency (DPE) | NCT02113839
Developing a COPD Case Finding Methodology for Primary Care | NCT01880177
Bronchial Infection in Patients With COPD and Frequent Exacerbations. | NCT03259022
Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax (2012) 4.06
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 3.36
Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30
Host Response to the Lung Microbiome in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 2.97
Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study. Thorax (2014) 2.95
The diagnosis of chronic obstructive pulmonary disease. Dtsch Arztebl Int (2014) 2.76
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52
The clinical features of the overlap between COPD and asthma. Respir Res (2011) 2.29
The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J (2014) 2.27
Understanding why patients with COPD get readmitted: a large national study to delineate the Medicare population for the readmissions penalty expansion. Chest (2015) 2.26
The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest (2011) 2.14
Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.06
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J (2012) 1.98
Early and Long-term Outcomes of Older Adults after Acute Care Encounters for Chronic Obstructive Pulmonary Disease Exacerbation. Ann Am Thorac Soc (2015) 1.93
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res (2011) 1.89
Association between chronic obstructive pulmonary disease and gastroesophageal reflux disease: a national cross-sectional cohort study. BMC Pulm Med (2013) 1.82
Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.77
Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Int J Chron Obstruct Pulmon Dis (2012) 1.68
Impact of co-morbidities on self-rated health in self-reported COPD: an analysis of NHANES 2001-2008. COPD (2013) 1.64
Racial differences in quality of life in patients with COPD. Chest (2011) 1.64
Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med (2013) 1.62
Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA (2016) 1.61
The role of the microbiome in exacerbations of chronic lung diseases. Lancet (2014) 1.55
Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema. Thorax (2014) 1.48
Evaluation of oxygen prescription in relation to hospital admission rate in patients with chronic obstructive pulmonary disease. BMC Pulm Med (2014) 1.47
Association of Psychological Disorders With 30-Day Readmission Rates in Patients With COPD. Chest (2016) 1.45
Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort. PLoS One (2016) 1.44
COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res (2011) 1.43
Radiological correlates and clinical implications of the paradoxical lung function response to β₂ agonists: an observational study. Lancet Respir Med (2014) 1.41
Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis (2012) 1.38
The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res (2013) 1.37
Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis (2012) 1.35
Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction. J Clin Invest (2013) 1.29
The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur Respir J (2012) 1.23
Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS One (2014) 1.23
The clinical impact of non-obstructive chronic bronchitis in current and former smokers. Respir Med (2013) 1.23
Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis (2014) 1.23
Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax (2012) 1.23
Differences in classification of COPD group using COPD assessment test (CAT) or modified Medical Research Council (mMRC) dyspnea scores: a cross-sectional analyses. BMC Pulm Med (2013) 1.21
Macrophage heterogeneity in respiratory diseases. Mediators Inflamm (2013) 1.20
Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res (2011) 1.15
Prediction of acute respiratory disease in current and former smokers with and without COPD. Chest (2014) 1.15
Clinical and computed tomographic predictors of chronic bronchitis in COPD: a cross sectional analysis of the COPDGene study. Respir Res (2014) 1.14
The Maastricht Study: an extensive phenotyping study on determinants of type 2 diabetes, its complications and its comorbidities. Eur J Epidemiol (2014) 1.13
Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India (2013) 1.13
Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int J Chron Obstruct Pulmon Dis (2012) 1.13
Benefits and harms of roflumilast in moderate to severe COPD. Thorax (2013) 1.12
Peripheral blood mononuclear cell gene expression in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol (2013) 1.12
COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis (2014) 1.11
Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet (2015) 1.11
The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One (2014) 1.10
Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2011) 1.08
Factors associated with change in exacerbation frequency in COPD. Respir Res (2013) 1.08
The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean Health Insurance Review and Assessment Service data. Int J Chron Obstruct Pulmon Dis (2013) 1.07
Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Br J Clin Pharmacol (2015) 1.07
Prevalence of chronic obstructive lung disease in Korea using data from the fifth Korea national health and nutrition examination survey. Korean J Fam Med (2015) 1.06
Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. Int J Chron Obstruct Pulmon Dis (2011) 1.05
Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One (2014) 1.04
Virus-induced exacerbations in asthma and COPD. Front Microbiol (2013) 1.04
Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J Chron Obstruct Pulmon Dis (2011) 1.04
Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis (2015) 1.03
Protection against Streptococcus pneumoniae lung infection after nasopharyngeal colonization requires both humoral and cellular immune responses. Mucosal Immunol (2014) 1.02
Canadian practice assessment in chronic obstructive pulmonary disease: respiratory specialist physician perception versus patient reality. Can Respir J (2013) 1.02
Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open (2014) 1.02
Chronic obstructive pulmonary disease. Indian J Med Res (2013) 1.02
Using an electronic medical record (EMR) to conduct clinical trials: Salford Lung Study feasibility. BMC Med Inform Decis Mak (2015) 1.01
Effectiveness of pharmaceutical care for patients with chronic obstructive pulmonary disease (PHARMACOP): a randomized controlled trial. Br J Clin Pharmacol (2014) 1.01
Emphysema distribution and annual changes in pulmonary function in male patients with chronic obstructive pulmonary disease. Respir Res (2012) 1.01
COPD symptoms in the morning: impact, evaluation and management. Respir Res (2013) 1.00
A review of national guidelines for management of COPD in Europe. Eur Respir J (2016) 0.99
A comparison of three multidimensional indices of COPD severity as predictors of future exacerbations. Int J Chron Obstruct Pulmon Dis (2013) 0.99
Contribution of the environment and comorbidities to chronic obstructive pulmonary disease phenotypes. Med Clin North Am (2012) 0.98
The chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implications. Curr Opin Pulm Med (2015) 0.98
Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res (2013) 0.98
Daily step count predicts acute exacerbations in a US cohort with COPD. PLoS One (2013) 0.98
Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res (2014) 0.97
Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. J Bras Pneumol (2013) 0.97
Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med (2015) 0.97
Agonistic induction of PPARγ reverses cigarette smoke-induced emphysema. J Clin Invest (2014) 0.97
Role of alveolar macrophages in chronic obstructive pulmonary disease. Front Immunol (2014) 0.96
Determinants of high-sensitivity cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. BMC Pulm Med (2012) 0.96
The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2013) 0.95
Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis (2013) 0.95
Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Med (2012) 0.95
Bacterial microbiome of lungs in COPD. Int J Chron Obstruct Pulmon Dis (2014) 0.94
NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study. Respir Res (2012) 0.94
Trends in management and outcomes of COPD patients in primary care, 2000-2009: a retrospective cohort study. NPJ Prim Care Respir Med (2014) 0.94
Oxidized phospholipids impair pulmonary antibacterial defenses: evidence in mice exposed to cigarette smoke. Biochem Biophys Res Commun (2012) 0.94
Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cell Mol Life Sci (2013) 0.94
Factors affecting mortality following emergency admission for chronic obstructive pulmonary disease. BMC Pulm Med (2014) 0.93
25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. BMC Pulm Med (2012) 0.93
Influence of diet and obesity on COPD development and outcomes. Int J Chron Obstruct Pulmon Dis (2014) 0.93
An Internet-Mediated Pedometer-Based Program Improves Health-Related Quality-of-Life Domains and Daily Step Counts in COPD: A Randomized Controlled Trial. Chest (2015) 0.93
Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med (2014) 0.92
Novel outcomes and end points: biomarkers in chronic obstructive pulmonary disease clinical trials. Proc Am Thorac Soc (2011) 0.92
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86
International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97
Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol (2008) 10.77
Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae. Nature (2005) 7.74
Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med (2004) 7.03
A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93
Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med (2013) 6.36
Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17
Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA (2002) 6.00
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17
Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature (2011) 4.92
Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 4.87
Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 4.73
An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49
Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med (2009) 4.27
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med (2004) 4.24
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest (2010) 3.91
The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology (2002) 3.91
Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70
C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 3.69
Systemic effects of smoking. Chest (2007) 3.63
Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med (2011) 3.58
Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 3.54
Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med (2007) 3.45
Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet (2010) 3.44
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
What is chronic obstructive pulmonary disease anyway?: Continua, categories, cut points, and moving beyond spirometry. Am J Respir Crit Care Med (2013) 3.39
Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Med (2005) 3.32
Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med (2006) 3.30
Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med (2006) 3.30
The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med (2012) 3.18
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09
Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA (2008) 3.01
Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med (2012) 3.00
Evolution of mortality over time in patients receiving mechanical ventilation. Am J Respir Crit Care Med (2013) 2.95
The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med (2007) 2.91
Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest (2003) 2.90
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87
Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA (2012) 2.85
Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 2.80
Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med (2010) 2.80
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2008) 2.66
Persistent endothelial dysfunction in humans after diesel exhaust inhalation. Am J Respir Crit Care Med (2007) 2.65
Risk factors for extubation failure in patients following a successful spontaneous breathing trial. Chest (2006) 2.60
Airway and systemic inflammation and decline in lung function in patients with COPD. Chest (2005) 2.59
'Highlights from this issue’ in the November issue of Thorax. Thorax (2013) 2.59
Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA (2013) 2.59
Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. Crit Care Med (2011) 2.55
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52
Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. Proc Natl Acad Sci U S A (2006) 2.51
Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ (2004) 2.39
Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med (2012) 2.38
Airway pressures, tidal volumes, and mortality in patients with acute respiratory distress syndrome. Crit Care Med (2005) 2.37
Systematic in vivo analysis of the intrinsic determinants of amyloid Beta pathogenicity. PLoS Biol (2007) 2.35
Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med (2011) 2.30
Disturbed intestinal integrity in patients with COPD: effects of activities of daily living. Chest (2014) 2.27
Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. Hum Mol Genet (2012) 2.24
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.21
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20
Differences in content and organisational aspects of pulmonary rehabilitation programmes. Eur Respir J (2013) 2.20
Conformational pathology of the serpins: themes, variations, and therapeutic strategies. Annu Rev Biochem (2009) 2.19
Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc Natl Acad Sci U S A (2004) 2.19
The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res (2005) 2.18
Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med (2009) 2.17
Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol (2002) 2.16
Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest (2009) 2.16